{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-117204","form_type":"8-K","ticker":"GRDX","cik":"0001604191","company_name":"GridAI Technologies Corp.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.944568+00:00","generated_at":"2026-05-30T00:56:04.519411+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Entero Therapeutics to reverse-merge with Journey Therapeutics, issuing 99% equity","bullets":["Entero (ENTO) signs binding term sheet to acquire all Journey equity; Journey holders get 99% of combined company.","Post-close, Journey CEO Henry Ji to become CEO and Chairman of the combined company.","Conditions include $5M equity financing, S-4 effectiveness, Nasdaq listing, and ENTO stockholder approval.","Combined entity will focus on Journey's NIC platform for oncology and Entero's GI pipeline (latiglutenase, adrulipase, capeserod).","NIC platform licensed from Mayo Clinic; early Phase 1 data in ovarian/endometrial cancer and non-Hodgkin's lymphoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-117204","json":"https://secwatch.observer/filing/0001104659-24-117204.json","markdown":"https://secwatch.observer/filing/0001104659-24-117204.md","text":"https://secwatch.observer/filing/0001104659-24-117204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924117204/0001104659-24-117204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924117204/tm2428268d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:56:04.519411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}